The British-Swedish pharmaceutical company AstraZeneca said that the number of blood clots among the 17 million people who received the vaccine “lower than would be expected in the General population.”
“About 17 million people in the EU and the UK got our vaccine, and the number of reported cases of blood clots lower than the hundreds of cases that would be expected in the General population,”said Ann Taylor, head of the medical department of the company.
AstraZeneca also said there is no evidence of an increased risk of blood clots from taking the drug. According to the company, there are currently only 15 cases of deep vein thrombosis and 22 pulmonary embolism cases in the EU and the UK. Also, during clinical trials, the number of cases of blood clots was lower in the group receiving the vaccine.
According to the company representatives, not a single batch of the vaccine used in Europe and the rest of the world has any quality problems. It is also reported that AstraZeneca has conducted and is conducting additional tests regularly, all tests meet strict quality criteria, and data is transmitted to regulatory authorities in each country, where an independent review is required before a batch of the vaccine is approved for use.
Earlier it was reported that the Austrian authorities, as a precautionary measure, decided to suspend the use of a batch of AstraZeneca vaccine in connection with the death of one vaccinated woman and the development of thromboembolism in another after receiving the vaccine. Austria’s example was followed by Estonia, Lithuania, Luxembourg, and Latvia. On Thursday, the use of the drug was also suspended by Denmark, Norway, and Iceland.